Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 27, 2007

Vaccinex and Teva Ink Antibody Development Alliance in MS and Oncology

  • Vaccinex entered into a collaboration with Teva Pharmaceutical Industries to develop and commercialize VX15, a human antibody discovered by Vaccinex. VX15 has the potential to improve efficacy in treating multiple sclerosis (MS) by both suppressing the body’s autoimmune response and blocking damage to the central nervous system, Vaccinex reports.

    According to the terms of the agreement, Teva will make an equity investment in Vaccinex and pay undisclosed fees, development milestones, and royalties on product sales to acquire an exclusive license for the development and commercialization of VX15 in MS and other disease indications. Vaccinex retains rights to oncology indications and will continue to conduct all preclinical development activities, which will be funded by Teva. Teva will have an option to participate as a co-development partner in oncology after Vaccinex completes Phase I trials.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »